[HTML][HTML] Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European …

A Angelis, A Lange, P Kanavos - The European Journal of Health …, 2018 - Springer
Background Although health technology assessment (HTA) systems base their decision
making process either on economic evaluations or comparative clinical benefit assessment …

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

SD Grosse - Expert review of pharmacoeconomics & outcomes …, 2008 - Taylor & Francis
Cost–effectiveness analyses, particularly in the USA, commonly use a figure of 50,000perlife-
yearorquality-adjustedlife-yeargainedasathresholdforassessingthecost …

[图书][B] Economic analysis in healthcare

S Morris, N Devlin, D Parkin, A Spencer - 2012 - books.google.com
Economic Analysis in Health Care, Second Edition is intended as a core textbook for
advanced undergraduate and postgraduate students of health economics. The authors …

The influence of costeffectiveness and other factors on nice decisions

H Dakin, N Devlin, Y Feng, N Rice, P O'neill… - Health …, 2015 - Wiley Online Library
Abstract The National Institute for Health and Care Excellence (NICE) emphasises that cost
effectiveness is not the only consideration in health technology appraisal and is increasingly …

NICE's cost effectiveness threshold

J Appleby, N Devlin, D Parkin - Bmj, 2007 - bmj.com
NICE's cost effectiveness threshold | The BMJ Skip to main content Intended for healthcare
professionals Access provided by Google Indexer Subscribe My Account My email alerts BMA …

Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set

H Dakin, A Gray, R Fitzpatrick, G MacLennan… - BMJ open, 2012 - bmjopen.bmj.com
Objectives Many UK primary care trusts have recently introduced eligibility criteria restricting
total knee replacement (TKR) to patients with low pre-operative Oxford Knee Scores (OKS) …

Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness

M Svensson, FOL Nilsson, K Arnberg - Pharmacoeconomics, 2015 - Springer
Abstract Objective The Swedish Dental and Pharmaceutical Benefits Agency (TLV) is the
government body responsible for deciding whether outpatient drugs are to be included in …

The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004

AH Harris, SR Hill, G Chin, JJ Li… - Medical Decision …, 2008 - journals.sagepub.com
Objective. To analyze the relative influence of factors in decisions for public insurance
coverage of new drugs in Australia. Data Sources. Evidence presented at meetings of the …

Exploring the social value of healthcare interventions: a stated preference discrete choice experiment

C Green, K Gerard - Health economics, 2009 - Wiley Online Library
Much of the literature on distributive preferences covers specific considerations in isolation,
and recent reviews have suggested that research is required to inform on the relative …

[PDF][PDF] Health technology assessment: lessons learned from around the world—an overview

JC O'Donnell, SV Pham, CL Pashos, DW Miller… - Value in health, 2009 - core.ac.uk
Few recent issues in drug development and health systems management have generated
more commentary, and more controversy, than health technology assessment (HTA). The …